Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in Vancouver-based AI drug creation company Absci soared on Wednesday after investment firm Needham & Co ...
JonesResearch analyst Debanjana Chatterjee initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci’s artificial intelligence-driven platform can design antibodies to ...
VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy ...
Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback